Aftercare hub
After Mounjaro and Wegovy: aftercare, maintenance, and regain
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-20
GLP-1 aftercare is the maintenance phase after stopping prescription weight-loss medication such as Mounjaro or Wegovy. The published evidence is consistent: roughly 82 percent of people regain at least a quarter of lost weight within 12 months of stopping (Oxford analysis, January 2026). Maintenance dose, resistance training and high protein intake reduce regain. PeptideClear is editorial commentary, not clinical advice; whether to taper, maintain or stop is a decision for the reader and a UK-licensed prescriber.
The four phases
Most UK private programmes assume a 12 to 18 month treatment cycle. Many people stop sooner because of cost, supply, or side effects. The phases below are typical, not prescriptive. Your prescriber will adapt.
Active treatment (months 0-12)
Focus: Dose progression, weekly habits, protein, resistance training
Risk: Muscle loss if protein is low. Bone density risk in older women. Plateau is normal.
Goal weight reached (month 12-18 typical)
Focus: Decision: continue at maintenance dose, taper, or stop. Speak with prescriber.
Risk: 95% of clinical-trial participants stayed on medication. Full stop is the highest-regain path.
Tapering (4-12 weeks)
Focus: Stepwise dose reduction. Keep all habits in place. Plan the food environment.
Risk: Hunger returns first. Cravings second. Adapt protein and sleep before the regain starts.
Off medication (month 18+)
Focus: Weight regain risk peaks at months 6-12 off. Re-entry is common and not a failure.
Risk: 82% regain at least 25% of lost weight in the first year off (Oxford analysis, Jan 2026).
What helps regain risk drop
- · Resistance training before, during, and after. Up to half of GLP-1 weight loss is non-fat. Lean mass is the regain insurance.
- · Protein at 1.4 to 1.8g per kg of goal body weight per day. Protein page.
- · A maintenance dose rather than a full stop, if your prescriber agrees and your finances allow. Trial data favours staying on medication.
- · Behaviour scaffolding (food environment, sleep, structured weekly review) before the regain wave hits.
- · Re-entry plan. If regain starts, restarting is normal and not a failure. Speak with your prescriber early, not late.
Open questions on aftercare in 2026
- · Does NHS Mounjaro have a defined off-ramp? Currently no. NHS treatment is up to two years per the NICE TA1026 commissioning guidance, with no nationally-funded maintenance pathway after.
- · Will Cohort 2 (launching 23 June 2026) get the same time-limited model? Yes, expected.
- · Are private clinics offering true maintenance dosing? Numan and Voy advertise it. Pharmacy-direct routes typically do not pause progression.
- · Does the Wegovy CV outcome indication (approved April 2026) change aftercare? Possibly. People with CV-disease eligibility may be told to stay on medication indefinitely.
Popular on PeptideClear
Ready to buy
Find a UK GLP-1 clinic or pharmacy
GMC-registered prescribers compared by price, consultation type, and refund policy. Editorial only. We do not prescribe.